-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

615.O2.6 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML

Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, Therapies
Monday, December 11, 2023: 2:45 PM-4:15 PM
San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Roland B. Walter, MD, PhD, MS, Fred Hutchinson Cancer Research Center and Hetty E. Carraway, MD, MBA, Cleveland Clinic
Carraway: Novartis: Consultancy, Other: Travel, Accommodations, Expenses , Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Other: Travel, Accommodations, Expenses , Speakers Bureau; Stemline Therapeutics: Consultancy, Speakers Bureau; Genentech: Consultancy; Daiichi: Consultancy; Celgene: Research Funding; Agios: Consultancy, Speakers Bureau; AbbVie: Other; Astex Pharmaceuticals: Other; Syndax: Other: DSMB; Takeda: Other.
Refining the delivery of chemotherapy for patients with AML is a focus of this session by introduction of novel therapies to current regimens as well as incorporation of MRD to (1) assess need to stratify to a more intensive treatment modality or (2) as a biomarker of response to therapies/reflective of clinical outcome.
2:45 PM

Yunxiang Zhang1*, Qiusheng Chen1*, Xiangqin Weng, Master1*, Yang Shen1*, Wen Wu1*, Jiong Hu1, Jie Hao2*, Ligen Liu, MD3 and Junmin Li1*

1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Shanghai Jing'an District Beizhan Hospital, Shanghai, China
3Shanghai Tongren Hospital, Shanghai, China

3:00 PM

Nigel H. Russell, MD1, Abin Thomas2*, Robert Hills3*, Ian Thomas4*, Amanda Gilkes2*, Nuria Almuina5*, Sarah Burns6*, Lucy Marsh7*, Georgia Andrew8*, Nicholas McCarthy9*, Jennifer Byrne10*, Rob Sellar, FRCPath, MBBChir11*, Richard J. Kelly, BSc, MD12*, Paul Cahalin13*, Ulrik Malthe Overgaard14*, Priyanka Mehta, MD, FRCPath, MRCP15*, Mike Dennis, MD, MRCP, FRCPath16, Steve Knapper4* and Sylvie D Freeman17

1Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
2Cardiff University, Cardiff, GBR
3University of Oxford, Oxford, GBR
4Cardiff University, Cardiff, United Kingdom
5Centre For Trials Research, Cardiff University, Cardiff, GBR
6Centre For Trials Research,Cardiff University, Cardiff, GBR
7Cardiff University, Cardiff, United Kingdom
8AstraZeneca, Gaithersburg
9University of Birmingham, UK, Brimingham, GBR
10Nottingham University Hospitals NHS Trust, Nottingham, GBR
11University College London, London, GBR
12Department of Haematology, St. James’s University Hospital, Leeds, United Kingdom
13Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, GBR
14Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
15University Hospitals Bristol NHS Foundation Trust, Bristol, GBR
16The Christie, Manchester, GBR
17Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

3:15 PM

Barbara De Moerloose, MD1*, Nira Arad-Cohen2*, Daniel Cheuk3*, Jose Maria Fernandez Navarro4*, Henrik Hasle5, Kirsi Jahnukainen6*, Gertjan J.L. Kaspers, MD, PhD7, Zhanna Kovalova8*, Birgitte Lausen9*, Ulrika Norén-Nyström, MD, PhD10*, Josefine Palle11*, Ramune Pasauliene12*, Cornelis Jan Pronk, MD, PhD13*, Kadri Saks14*, Anne Maria Tierens, MD, PhD15,16, Bernward Zeller, PhD17* and Jonas Abrahamsson18*

1Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium
2Department of Pediatric Hemato-Oncology, Rambam Health Care Campus, Haifa, Israel;, Haifa, Israel
3Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital, University of Hong Kong, Hong Kong, China
4Department of Pediatric Hemato-Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
5Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
6Children's Hospital, University of Helsinki and Helsinki University Central Hosp, Helsinki, FIN
7VU University Medical Center, Utrecht, Netherlands
8Department of Pediatric Oncology/Hematology, Children's Clinical University Hospital, Riga, Latvia
9Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Denmark, Copenhagen, Denmark
10Department of Clinical Sciences, Pediatrics, Umeå University Hospital, Umeå, Sweden
11Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
12Center for Pediatric Oncology and Hematology, Vilnius University Children’s Hospital, Vilnius, Lithuania
13Childhood Cancer Center, Skåne University Hospital, Lund, Sweden
14Department of Hematology Oncology, Tallinn Children´s Hospital, Tallinn, Estonia
15Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada
16Laboratory Medicine Program, University Health Network, Toronto, ON, Canada
17Department of Pediatric Hematology-Oncology, Oslo University Hospital, Oslo, Norway
18Institution for Clinical Sciences, Department of Pediatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden

3:30 PM

Alexander Perl1, Harry P. Erba, MD, PhD2, Pau Montesinos, PhD, MD3*, Radovan Vrhovac, MD, PhD4*, Elzbieta Patkowska, MD5*, Heeje Kim, MD, PhD6, Pavel Zak7*, Po-Nan Wang, MD8*, Jaime E Rohrbach, PhD9*, Ken C N Chang, PhD10*, Li Liu11*, Yasser Mostafa Kamel12*, Karima Imadalou13*, Arnaud Lesegretain14*, Jorge Cortes, MD15, Mikkael A. Sekeres, MD16, Hervé Dombret17*, Sergio Amadori, MD18, Jianxiang Wang, MD19, Richard F Schlenk20* and Mark J. Levis, MD, PhD21

1Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
2Duke Cancer Institute, Durham, NC
3Hospital Universitari i Politecnic la Fe, Valencia, Spain
4University Hospital Centre Zagreb, Zagreb, Croatia
5Hematology, IHIT Institute of Hematology and Blood Transfusion Warsaw, Warsaw, Poland
6Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
7University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
8Chang Gung Medical Foundation, Linkou, Taiwan
9Daiichi Sankyo, Basking Ridge, NJ
10Daiichi Sankyo, Basking Ridge
11Daiichi Sankyo, Inc, Basking Ridge
12Daiichi Sankyo, Inc., Basking Ridge
13Daiichi Sankyo, Inc, Basking Ridge, NJ
14Daiichi Sankyo Inc., Basking Ridge, NJ
15Georgia Cancer Center, Augusta University, Augusta, GA
16Sylvester Cancer Center, University of Miami, Miami, FL
17Saint Louis Hospital, University of Paris, Paris, FRA
18Tor Vergata Polyclinic Hospital Rome, Rome, ITA
19Institute of Hematology and Blood Diseases Hospital, Tianjin, China
20Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
21Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD

3:45 PM

Alexandre Bazinet, MD1*, Guillermo Garcia-Manero, MD2, Nicholas J. Short, MD3, Yesid Alvarado Valero, MD3, Tareq Abuasab, MD3*, Md Rabiul Islam, MD, MPH4*, Kathryn Montalbano1*, Ghayas C. Issa5, Abhishek Maiti, MD1, Musa Yilmaz, MD3*, Nitin Jain, MD3, Lucia Masarova, MD3, Steven M. Kornblau, MD3, Elias Jabbour6, Guillermo Montalban-Bravo, MD7, Sherry Pierce, BSN, BA3*, Courtney D. DiNardo, MD, MSc3, Tapan M. Kadia, MD3, Naval Daver, MD3, Marina Y. Konopleva8, Hagop M. Kantarjian, MD9 and Farhad Ravandi, MD, MBBS10

1Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
6University of Texas M.D. Anderson Cancer Ctr., Houston, TX
7The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
9Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
10University of Texas- MD Anderson Cancer Center, Houston, TX

4:00 PM

Xiaoping Li, PhD1*, Xiaoyan Li2*, Yanling Jin3*, Zucong Chen4*, Yonglin Shen5*, Zhongtao Yuan, MD1*, Lin Liu1*, Yu Li, MD1*, Le Luo, MD1*, Shiqian Hou6*, Chaoyang Zhou7*, Chie Qiu8*, Kui Zhang9*, Chunfu Li, PhD10,11, Yang Liang, MD, PhD12 and Sanbin Wang Sr., MD, PhD1*

1Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, China
2The First People's Hospital of Baoshan, Baoshan, CHN
3The First People's Hospital of Qujing, Qujing, China
4Dehong People's Hospital, Dehong, China
5The People's Hospital of Honghe, Honghe, China
6The People's Hospital of Yuxi, Yuxi, China
7The People's Hospital of Chuxiong, Chuxiong, China
8Northeast Central Hospital of Yunnan Province, Zhaotong, China
9The Second People's Hospital of Qujing, Qujing, China
10Nanfang Hospital, Guangzhou, Guangdong, CHN
11Nanfang-Chunfu Children‘s Institute of Hematology&Oncology, Dongguan, China
12Yale University School of Medicine Yale Cancer Center, Guangzhou, Guangdong, China

*signifies non-member of ASH